Literature DB >> 32207101

A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain.

Harrison Dermer1, Daniella Lent-Schochet2, Despoina Theotoka1, Christian Paba3, Abdullah A Cheema4, Ryan S Kim5, Anat Galor6.   

Abstract

Despite being a common presenting symptom to eye-care clinics, many ophthalmologists have difficulty diagnosing and managing ocular surface pain. The purpose of this review is to discuss potential causes of ocular surface pain, focusing on both nociceptive and neuropathic aetiologies. Specifically, we outline an approach to the diagnosis of ocular surface pain and focus on various management strategies, providing supporting evidence on the efficacy of various treatments.

Entities:  

Mesh：

Year:  2020        PMID： 32207101     DOI： 10.1007/s40265-020-01282-3

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  204 in total

Review 1.  Ectropion.

Authors:  Eliana Guimaraes de Menezes Bedran; Maria Valéria Correia Pereira; Taliana Freitas Bernardes
Journal:  Semin Ophthalmol       Date:  2010-05       Impact factor: 1.975

2.  Oral azithromycin for the treatment of meibomitis.

Authors:  Jonathan B Greene; Bennie H Jeng; Robert E Fintelmann; Todd P Margolis
Journal:  JAMA Ophthalmol       Date:  2014-01       Impact factor: 7.389

3.  Epidemiology of discordance between symptoms and signs of dry eye.

Authors:  Erin S Ong; Elizabeth R Felix; Roy C Levitt; William J Feuer; Constantine D Sarantopoulos; Anat Galor
Journal:  Br J Ophthalmol       Date:  2017-08-18       Impact factor: 4.638

4.  Treatment of dry eye by autologous serum application in Sjögren's syndrome.

Authors:  K Tsubota; E Goto; H Fujita; M Ono; H Inoue; I Saito; S Shimmura
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

Review 5.  Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.

Authors:  Ralf Baron; Andreas Binder; Gunnar Wasner
Journal:  Lancet Neurol       Date:  2010-08       Impact factor: 44.182

6.  [Neurostimulation of the supraorbital nerve with the Cefaly device - a new method for the treatment of migraine].

Authors:  G R Tabeeva
Journal:  Zh Nevrol Psikhiatr Im S S Korsakova       Date:  2019

Review 7.  Ocular Demodicosis as a Potential Cause of Ocular Surface Inflammation.

Authors:  Xiaohui Luo; Jing Li; Chuan Chen; Scheffer Tseng; Lingyi Liang
Journal:  Cornea       Date:  2017-11       Impact factor: 2.651

8.  The efficacy of tea tree face wash, 1, 2-Octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis.

Authors:  Orla Murphy; Veronica O'Dwyer; Aoife Lloyd-McKernan
Journal:  Cont Lens Anterior Eye       Date:  2017-10-23       Impact factor: 3.077

9.  Pain as the fifth vital sign: exposing the vital need for pain education.

Authors:  Natalia E Morone; Debra K Weiner
Journal:  Clin Ther       Date:  2013-10-18       Impact factor: 3.393

10.  Safety and efficacy of doxycycline in the treatment of rosacea.

Authors:  Sheila Valentín; Adisbeth Morales; Jorge L Sánchez; Abimael Rivera
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-08-12
View more
  3 in total

1.  Corneal Confocal Microscopy Features and Tear Molecular Profile in Study Participants with Discordance between Ocular Surface Disease Clinical Signs and Discomfort.

Authors:  Sharon D'Souza; Rohit Shetty; Archana Padmanabhan Nair; Ruchika Agrawal; Mor M Dickman; Pooja Khamar; Rudy M M A Nuijts; Arkasubhra Ghosh; Swaminathan Sethu
Journal:  J Clin Med       Date:  2022-04-25       Impact factor: 4.964

2.  Treatment Response to Gabapentin in Neuropathic Ocular Pain Associated with Dry Eye.

Authors:  Hyeon-Jeong Yoon; Jonghwa Kim; Kyung Chul Yoon
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

3.  Differential Effects of Treatment Strategies in Individuals With Chronic Ocular Surface Pain With a Neuropathic Component.

Authors:  Sneh Patel; Rhiya Mittal; Elizabeth R Felix; Konstantinos D Sarantopoulos; Roy C Levitt; Anat Galor
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.